ADVERTISEMENT

Companies

A Decade On, How Deep Do Regeneron’s Oncology Foundations Go?

A Decade On, How Deep Do Regeneron’s Oncology Foundations Go?

Regeneron’s clinical and commercial oncology leaders talk to In Vivo about making good on the company’s oncology strategy and pushing the commercial accelerator in a post-Sanofi world.

Deals In Depth: September 2024

Deals In Depth: September 2024

Three $1bn+ alliances were penned in September.

Schrödinger’s Akinsanya On Low-Risk Pipeline Growth And Platform Evolution

Schrödinger’s Akinsanya On Low-Risk Pipeline Growth And Platform Evolution

Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?

Meet The Latest Radiopharmaceuticals Player

Meet The Latest Radiopharmaceuticals Player

Sanofi and Orano Med have kicked off a joint venture worth $1.9bn to develop alpha-emitting cancer therapies, underscoring the importance of this space to big pharma.

ML-Based Neuromodulation, Tele-Robotic Medical Imaging Among Octane Medical Innovation Forum Highlights

ML-Based Neuromodulation, Tele-Robotic Medical Imaging Among Octane Medical Innovation Forum Highlights

Start-ups pitched a diverse deck of innovative technologies to three judges and an audience of potential investors, strategics and physicians at the Octane Medical Innovation Forum in Irvine, CA. Highlights include neuromodulation company Sinaptica Therapeutics, which won the competition for both “People’s Choice” and “Judge’s Choice.”

From PhD To Unicorn: Mammoth CEO On Pharma Deals and Squishy Biology

From PhD To Unicorn: Mammoth CEO On Pharma Deals and Squishy Biology

Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.

Stock Watch: Two Elephants In The Q3 Room

Stock Watch: Two Elephants In The Q3 Room

New product launches come with great expectations, which are sometimes unrealistic. This can lead to disappointment. Lately, market access restrictions are exacerbating sales challenges.

The Anatomy Of Astellas And Poseida's CAR-T Deal

The Anatomy Of Astellas And Poseida's CAR-T Deal

Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.

Fusion CEO Talks AZ Deal Making And Canada’s Blossoming Biotech Ecosystem

Fusion CEO Talks AZ Deal Making And Canada’s Blossoming Biotech Ecosystem

Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.

Itovebi Approval Is First Step In Roche’s Breast Cancer Comeback

Itovebi Approval Is First Step In Roche’s Breast Cancer Comeback

The Swiss company is aiming to regain its innovator status and expand its offering across all breast cancer settings. Approval of Itovebi is just the start.